The Peptide
Benchmark
Independent vendor reviews, deep-dive peptide guides, and aggregated research — all in one place. No fluff, no bias, just data.
Vendor Benchmark Rankings
Source-linked benchmark records blended from Finnrick and Peptide Critic when both exist, then normalized onto a shared 10-point benchmark scale and ordered by a confidence-weighted rank score.
Finnrick sync: May 14, 2026, 6:23 AM. Peptide Critic sync: May 14, 2026, 6:23 AM. Showing 4 of 254 scoreable vendors from a 263-entry merged dataset.
Vendors currently scored by both Finnrick and Peptide Critic.
Entries with enough source depth to keep most of their raw benchmark signal.
Combined Finnrick test records and Peptide Critic reviews informing the board.
EZ Peptides
EZ Peptides is currently our only disclosed referral partner, so it gets an explicit PeptideBenchmark pick label. That badge is editorial and separate from the source-derived benchmark data shown below.
Benchmark score is the normalized source score. Rank score is the confidence-weighted ordering value. The signal bar and evidence count help show how much underlying data is holding each card up.
- 6 Finnrick test records tracked
- 66 Peptide Critic reviews captured
- United States
- 24 Finnrick test records tracked
- 31 Peptide Critic reviews captured
- United States
- 73 Finnrick test records tracked
- 9 Peptide Critic reviews captured
- United States
- 47 Finnrick test records tracked
- 6 Peptide Critic reviews captured
- United States
Peptides by Category
Explore peptides organized by their primary function. Each category includes comprehensive profiles, dosing guides, and comparison charts.
Trending Peptides
Current profile coverage pulled directly from the peptide collection, mixing FDA-approved medicines with closely watched research compounds.
Peptide News Wire
FDA.gov FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List 15 days ago PubMed Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review. 4 days ago ClinicalTrials.gov A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) yesterday FDA.gov Compounding Quality Center of Excellence | Instructor-Led Trainings 11 hours agoFrom the Blog
Collection-backed notes on benchmark methodology, source quality, and how to interpret peptide vendor signal without overclaiming certainty.
Amycretin is Novo Nordisk's unimolecular GLP-1 and amylin receptor agonist, now in Phase 3 for obesity in both oral and subcutaneous forms. Here is what the trial data actually show.
SLU-PP-332 is an ERR agonist sold by peptide vendors as an exercise mimetic, but it is a synthetic small molecule, not a peptide, and all efficacy data remain preclinical.
VIP peptide, or vasoactive intestinal peptide, has a real clinical literature, a controversial role in the Shoemaker CIRS protocol, and an unusual FDA Category 1 compounding status in 2026.